Background: Accumulating evidence reveals that long non-coding RNAs (lncRNAs) play a crucial role in pathogenesis of non-small-cell lung cancer (NSCLC), providing a new concept to exploit novel biomarkers for diagnosis, prognosis or therapeutic target of NSCLC. The intention of this study was to examine the viability of lncRNA PRAL as a biomarker for NSCLC and explore its biological function in NSCLC cell lines. Methods: PRAL transcription levels were evaluated using Q-PCR. Receiver operating characteristic (ROC) curve analyses were used to evaluate the diagnostic value for NSCLC patients. Kaplan-Meier analysis and log-rank test were performed to assess the correlation between PRAL expression and the clinical outcomes on overall survival (OS) and progression-free survival (PFS). 
INTRODUCTION
The most malignant lung cancer or cancer-associated disease kills millions of people worldwide every year, and non-small cell lung cancer (NSCLC) accounts for 80 -85% of all deaths. Albeit tremendous efforts have been focused on the diagnosis and the treatment of lung cancer, the great progress in clinical therapy for lung cancer has not changed the fact that the overall survival time of NSCLC remains extremely low. Obviously, the lack of effective molecular biomarkers for diagnosis and prognosis has led to the discovery of lung cancer at advanced stages in many cases. LncRNAs -a class of non-coding RNA with longer than 200 nucleotides are gaining widespread attention in recent years. So far, over 3,000 lncRNAs have been identified, at the same time, well-studied lncRNAs occupy only a small number of them. The existing evidence shows lncRNAs are associated with many cellular processes such as chromatin remodeling, genetic printing, splicing regulation, RNA decay, cell cycle control, and translational regulation [1, 2] . Abnormal lncRNA expressions involved in cell proliferation, metastasis, and metabolism are a common phenomenon among multiple cancers including lung cancer [3, 4] . Recent research revealing lncRNAs play a vital role in pathogenesis of NSCLC has offered fresh ideas to explore novel biomarkers for diagnosis, therapy, and prognosis of NSCLC [5] [6] [7] [8] . Recently, an interesting paper was published by Dr. Zhou in which he discovered the down-regulation of the lnc-RNA PRAL in HCC (hepatocellular carcinoma) tissues compared with corresponding adjacent tissues, and over-expression of PRAL inhibited HCC cell proliferation both in vitro and in vivo by regulation of P53 [9] . Su et al. first identified PRAL as a tumor suppressor in human lung cancer with decreased transcript level [10] ; however, more detailed mechanisms underlying the regulatory role of PRAL in NSCLC need to be proven. In our study, we tried to appraise the possibility of lnc-RNA PRAL as a biomarker in NSCLC and explore the underlining mechanism of tumor suppressor in NSCLC. To attain this goal, we used RT-PCR to analyze the expression of PRAL in vitro. Cell proliferation, migration and invasion assays were performed in NSCLC cell lines.
MATERIALS AND METHODS

NSCLC clinical samples and data collection
One hundred sixty-four NSCLC cancer samples and corresponding adjacent normal tissues were harvested from patients whose diagnosis revealed NSCLC and who had undergone curative surgical removal of a primary lesion at Linyi Cancer Hospital of Shandong province between March 2008 and February 2013. In addition, 30 healthy control samples were obtained from people without NSCLC or other malignancies. Pathological evaluation established the histological classification and staging in all of the patients. None of the patients had either radiotherapy or chemotherapy before or after surgery until the disease recurred. This study was approved by the Research Ethics Committee of the Linyi Cancer Hospital. Written informed consent forms were obtained from all subjects. Patients who received induction therapy were excluded from the study. Samples were histologically confirmed to have been obtained from tumor masses. A portion of each sample was frozen immediately after surgical resection and stored at -80°C until use. The clinicopathological features of the specimens were assessed according to the World Health Organization classification system and the tumor, lymph node, metastasis (TNM) staging system. Sizes of tumors were determined during operation. Clinical characteristics of all the patients were summarized in Table  1 . Overall survival (OS) time was defined as the interval between the dates of the initial surgery and death. Progression-free survival (PFS) time was calculated from the date of the initial surgery until the first evidence of tumor progression. All patients had experienced a close follow-up observation since the date of surgical resection for disease recurrence at no less than 2-month intervals during the follow-up period lasting 60 months.
Total RNA isolation and quantitative real-time polymerase chain reaction (qPCR) Using Trizol reagent (Invitrogen, Shanghai, China), total RNA was extracted from tissues according to the manufacturer's instructions. The concentration and purity of the total RNA were detected with a Nano Drop ND-2000 Spectrophotometer (Thermo Scientific) at 260 nm. cDNA was converted from total RNA by using a Reverse Transcription Kit (Takara, Dalian, China) according to the instructions. qPCR was performed with SYBR Green (Takara) and the data collection was carried out on the M×3000P StrataGene QPCR (Agilent Technologies) according to the manufacturer's instructions to detect the expression of lncRNA PRAL. qPCR reactions were performed in triplicate. We chose GAPDH as an internal control. The primers were synthesized by Biosune (Shanghai, China) and primer sequences were as follows: PRAL: forward: 5'-GGCAGAGCTCGCTTGGT-3 and reverse: 5'-GAAACTCCGTCTCCGCTAA-3'. P53: forward: 5'-TTGAGGTGCGTGTTTGTG-3' and reverse: 5'-CTGGGCATCCTTGAGTTC-3'. GAPDH: forward: 5'-CGGATTTGGTCGTATTGGG-3' and reverse: 5'-CTGGAAGATGG TGATGGGATT-3'.
Cells and cell culture
Three NSCLC cell lines (A549, H441, H522) and normal lung epithelial cell line MRC-5 were all purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured with recommended methods. Cell lines were tested by the MycoAlert™ Mycoplasma Detection Kit (Lonza Group Ltd, Basel, Switzerland) before the experiment to make sure they were free of mycoplasma contamination.
Transfection of PRAL Expression Plasmid
The PRAL sequence was synthesized according to the full-length PRAL sequence (NCBI) and was cloned into pCDNA3.0 vector (Invitrogen, Shanghai, China). Cell transfection was performed with lipofectamine 2000 reagent (Invitrogen, NY, USA) according to the manufacture's instructions. An empty vector as a control was transfected into cells.
Cell Growth assay: proliferation
A cell proliferation assay was performed by MTS kit (Roche Applied Science) following the manufacturer's protocol. The pcDNA-PRAL or empty vector-transfected cells were cultured in 96-well plates (2 -3,000/well) in triplicate. After 48 hours, cell viability was measured.
Boyden chamber assay: migration and invasion
Migration and invasion assays were performed according to the manufacturer's protocol. In brief, after transfection for 36 hours with pcDNA-PRAL or empty vector, 5 x 10 4 cells without serum were inoculated into the upper chamber (8-μm pore size; Millipore) for migration assays. 10 x 10 4 cells without serum were placed into the upper chamber pre-coated with Matrigel for invasion assays and total FBS medium was added in the lower chamber. After incubation for 24 hours, the upper layer of cells were removed, and the cells on the lower surface were fixed and stained. Images were photographed using an IX71 inverted microscope (Olympus, Tokyo, Japan) and counted. All experiments were performed in triplicate.
Statistical analysis
IBM SPSS Statistics for Windows, Version 19.0. (IBM Corp., Armonk, NY, USA) was used for all experimental data analysis from three independent experiments, and results were expressed as mean ± SD. One-way analysis of variance (ANOVA) was applied to analyze the differences of PRAL expression levels between NSCLC tissues and adjacent normal tissues. Pearson's chi-square and Student's t-tests were performed to determine the differences between PRAL expression levels and clinicopathological factors. Survival analysis was performed using the Kaplan-Meier method, and the log-rank test was performed to calculate the difference in survival. Survival data were evaluated using univariate and multivariate Cox proportional hazards regression models. A p-value of < 0.05 was considered statistically significant. Variables with a value of p < 0.05 in the univariate analysis were used in the subsequent multivariate analysis. A receiver operating characteristic (ROC) curve was established to evaluate the diagnostic value for the performance of PRAL. All graphs were plotted by GraphPad Prism 5.0.
RESULTS
The expression of PRAL was decreased in NSCLC and negatively correlated with cancer progression To determine whether lncRNA PRAL plays a role in NSCLC, we first detected the relative expression levels of PRAL in NSCLC tumors (n = 164) compared with their corresponding adjacent normal tissues (n = 164) using qPCR; 30 healthy tissues were also measured. PRAL expression levels were significantly decreased in the majority of the NSCLC tumor tissues compared with corresponding adjacent normal tissues (p < 0.0001) and healthy tissues (p < 0.0001) (Figure 1 ). These findings suggested that downregulated PRAL expression may be associated with NSCLC pathogenesis.
Down-regulated expression of PRAL is an independent prognostic predictor for patients with NSCLC
To further ascertain the role of PRAL in determining the clinical significance of NSCLC, we used the Chisquare test to evaluate the correlation between the level of PRAL expression and the clinicopathological factors in NSCLC. According to the median value of PRAL expression levels in cancer tissues, we divided the samples into high PRAL expression groups (above the mean, n = 82) and low PRAL expression groups (below the mean, n = 82). We discovered that there was an obvious negative correlation between decreased PRAL levels and advanced TNM stage (χ 2 = 8.826, p = 0.003). As shown in Table 1 , no relationship between PRAL expression and other factors were found within our study. Taken together, these results demonstrated that PRAL could play an important role in the progression of NSCLC. Furthermore, the receiver operating characteristic (ROC) curve and the area under the ROC curves (AUC) analysis were performed on NSCLC tissues and corresponding adjacent non-tumorous tissues to investigate the expression characteristics of PRAL as potential biomarkers of NSCLC. The ROC curve revealed strong separation between the NSCLC tissues and the control group, with an AUC of 0.8546 (95% CI: 0.7993 to 0.9098; p < 0.0001) for PRAL (Figure 2 ).
Down-regulated expression of PRAL predicts poor prognosis in patients with NSCLC
In order to evaluate the prognostic value of lncRNA PRAL expression for NSCLC, we used Kaplan-Meier analysis and log-rank test to assess the correlation between PRAL expression and the clinical outcomes on overall survival (OS) and progression-free survival (PFS). As shown in Figure 3A and B, the 5-year OS for high PRAL expression NSCLC patients was 12.2%, whereas for low PRAL expression patients it was only 8.5%. The median OS and PFS for high PRAL expression was inferior to that with low PRAL expression (OS, 42 months vs. 33.5 months; PFS, 30 months vs. 24.5 months). In general, patients with low PRAL expression level had poorer OS (p = 0.0122) and PFS (p = 0.0317). These results indicated that decreased expression of PRAL significantly decreased the survival time of NSCLC patients. To further confirm the prognostic role of PRAL in NSCLC patients, the univariate and multivariate survival analyses (Cox proportional hazards regression model) were performed. Univariate analysis found that three prognosis factors (histological grade (low, middle, or high), TNM stage (I/II, III/IV), and PRAL expression (low, high) were statistically significant risk factors. The other clinicopathological characteristics, such as gender (male, female), age (≤ 60, ≥ 60), tumor size (≤ 3 cm, > 3 cm), history of smoking (ever, never), and lymph node metastasis were found to be statistically insignificant prognosis factors (p > 0.05). Multivariate analysis further demonstrated that PRAL expression, histological classification, and TNM stage remained significantly correlated with poor survival and progression-free survival of NSCLC patients (p < 0.05) ( Table  2 ). In conclusion, these results showed that down-regulated expression of PRAL might play an important role in NSCLC development.
Overexpression of PRAL inhibited cell proliferation
To appraise the biological functions of PRAL in NSCLC, we first surveyed the influence of PRAL expression on the proliferation NSCLC cells. Overexpression of PRAL was performed through transient transfection of pcDNA-PRAL into A549 or H441 cells. The expression of PRAL was meaningfully up-regulated as compared with the same cells without transfection or empty vector transfected ( Figure 4A ). Corresponding to that, abnormal expression of PRAL hurt the growth of A549 and H441cells as compared to the control or empty vector-transfected cells ( Figure 4B and 4C). 
Overexpression of PRAL inhibited cell migration and invasion
To further evaluate the importance of PRAL in NSCLC development, we suspected ectopic PRAL expression might change the metastatic potential of NSCLC cells. We selected two highly metastatic potential cell lines to perform Boyden chamber migration assays to survey cell migration. The up-regulated PRAL expression expressively decreased the migration of H441 and H522 cells ( Figure 5A ). Likewise, the invasiveness of H441 transfected with pcDNA-PRAL was also markedly weakened ( Figure 5B ). Taken together, these results indicated that abnormal expression of PRAL resisted the viability of migration and invasion of NSCLC cells. The biological functions of PRAL in NSCLC may change tumor development by regulating cell proliferation and metastasis.
DISCUSSION
The conventional view of gene regulation in biology has centered on protein-coding genes. However, many lncRNAs have been characterized and accumulating evidence shows that they play an important role in tumorigenesis and development. The aberrant expressions of specific lncRNAs in cancer may serve as independent biomarkers for diagnosis and prognosis. LncRNAs in NSCLC are still a rising field with only a handful of lncRNAs known to be involved in NSCLC development such as HOTAIR [11] [12] [13] , MEG3 [14, 15] , GAS5 [16] [17] [18] [19] , and H19 [20] [21] [22] . These findings indicate that, lncRNAs could serve as diagnostic and prognostic biomarkers. However, the overall pathophysiological roles of lncRNA PRAL in NSCLC cancer remain unknown. PRAL, a lncRNA transcript is a new candidate lncRNA that was previously reported to down-regulated in hepatocellular carcinoma (HCC). Unusual PRAL expression was meaningfully associated with reduced survival of HCC patients [9] . However, the expression and clinical significance of PRAL in NSCLC remains largely unclear. In our present study, we explored the correlation between lncRNA PRAL expression levels and clinicopathological characteristics of patients with NSCLC. Our results showed that the expression of PRAL is down-regulated in NSCLC (Figure 1 ). Besides, we found that decreased PRAL expression was negatively correlated with higher histological grade and advanced TNM stage. Furthermore, we also evaluated the prognostic value of PRAL by Kaplan-Meier and Cox regression analyses. More importantly, we also confirmed that PRAL expression was independent predictors for OS and PFS. These results suggest lncRNA PRAL may be a novel indicator of poor prognosis in NSCLC development and progression. The facts that overexpression PRAL significantly inhibited cell proliferation, migration, and invasion in NSCLC cell lines also indicated PRAL may be a potential therapeutic target.
CONCLUSION
Our results showed that PRAL may play a key role in NSCLC as an indicator of poor survival rate and as a poor prognostic marker in NSCLC patients. The biological functions of up-regulated PRAL in NSCLC included inhibition of cell growth, migration, and invasion. In further studies, we will expand the investigation of samples, trying to identify the molecular mechanisms of lncRNA PRAL.
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